Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.

Ixekizumab may improve renal function in psoriasis / Amoruso, Giuseppe Fabrizio; Nisticò, Steven Paul; Iannone, Luigi; Russo, Emilio; Rago, Giuseppe; Patruno, Cataldo; Bennardo, Luigi. - In: HEALTHCARE. - ISSN 2227-9032. - 9:5(2021). [10.3390/healthcare9050543]

Ixekizumab may improve renal function in psoriasis

Nisticò, Steven Paul
;
2021

Abstract

Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.
2021
ixekizumab; psoriasis; chronic renal failure
01 Pubblicazione su rivista::01i Case report
Ixekizumab may improve renal function in psoriasis / Amoruso, Giuseppe Fabrizio; Nisticò, Steven Paul; Iannone, Luigi; Russo, Emilio; Rago, Giuseppe; Patruno, Cataldo; Bennardo, Luigi. - In: HEALTHCARE. - ISSN 2227-9032. - 9:5(2021). [10.3390/healthcare9050543]
File allegati a questo prodotto
File Dimensione Formato  
Amoruso_ Ixekizumab_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 564.54 kB
Formato Adobe PDF
564.54 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1687128
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 27
social impact